A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
Plaque PsoriasisThe main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria:
1. Plaque psoriasis for at least 6 months.
2. Moderate to severe disease.
3. Candidate for phototherapy or systemic therapy.
Exclusion Criteria:
1. Other forms of psoriasis.
2. History of recent infection.
3. Prior exposure to TAK-279 or active comparator.
Other protocol defined inclusion/exclusion criteria apply.
Study Location
Dermatology Research Institute, Inc. - Probity - PPDS
Dermatology Research Institute, Inc. - Probity - PPDSCalgary, Alberta
Canada
Contact Study Team
Wiseman Dermatology Research Inc. - Probity - PPDS
Wiseman Dermatology Research Inc. - Probity - PPDSWinnipeg, Manitoba
Canada
Contact Study Team
DermEffects - Probity - PPDS
DermEffects - Probity - PPDSLondon, Ontario
Canada
Contact Study Team
Oshawa Clinic-117 King St
Oshawa Clinic-117 King StOshawa, Ontario
Canada
Contact Study Team
Canadian Dermatology Centre - Probity - PPDS
Canadian Dermatology Centre - Probity - PPDSToronto, Ontario
Canada
Contact Study Team
Siena Medical Research
Siena Medical ResearchWestmount, Quebec
Canada
Contact Study Team
CaRe Clinic-Red Deer
CaRe Clinic-Red DeerRed Deer, Alberta
Canada
Contact Study Team
Dermatrials Research
Dermatrials ResearchHamilton, Ontario
Canada
Contact Study Team
The Centre for Clinical Trials Inc. - Probity - PPDS
The Centre for Clinical Trials Inc. - Probity - PPDSOakville, Ontario
Canada
Contact Study Team
Dr. S. K. Siddha Medicine Professional Corporation - Probity - PPDS
Dr. S. K. Siddha Medicine Professional Corporation - Probity - PPDSRichmond Hill, Ontario
Canada
Contact Study Team
XLR8 Medical Research - Probity - PPDS
XLR8 Medical Research - Probity - PPDSWindsor, Ontario
Canada
Contact Study Team
Alberta DermaSurgery Centre - Probity - PPDS
Alberta DermaSurgery Centre - Probity - PPDSEdmonton, Alberta
Canada
Contact Study Team
Brunswick Dermatology Centre - Probity - PPDS
Brunswick Dermatology Centre - Probity - PPDSFredericton, New Brunswick
Canada
Contact Study Team
Lynderm Research Inc - Probity - PPDS
Lynderm Research Inc - Probity - PPDSMarkham, Ontario
Canada
Contact Study Team
SKiN Centre for Dermatology - Peterborough - Probity - PPDS
SKiN Centre for Dermatology - Peterborough - Probity - PPDSPeterborough, Ontario
Canada
Contact Study Team
Toronto Research Centre - Probity - PPDS
Toronto Research Centre - Probity - PPDSToronto, Ontario
Canada
Contact Study Team
Skinsense Medical Research - 411 2nd Ave N - Probity - PPDS
Skinsense Medical Research - 411 2nd Ave N - Probity - PPDSSaskatoon, Saskatchewan
Canada
Contact Study Team
VIDA Dermatology - Probity - PPDS
VIDA Dermatology - Probity - PPDSEdmonton, Alberta
Canada
Contact Study Team
Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity - PPDS
Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity - PPDSHamilton, Ontario
Canada
Contact Study Team
DermEdge Research - Probity - PPDS
DermEdge Research - Probity - PPDSMississauga, Ontario
Canada
Contact Study Team
Centre For Dermatology and Cosmetic Surgery - Probity - PPDS
Centre For Dermatology and Cosmetic Surgery - Probity - PPDSRichmond Hill, Ontario
Canada
Contact Study Team
Alliance Clinical Trials - Probity - PPDS
Alliance Clinical Trials - Probity - PPDSWaterloo, Ontario
Canada
Contact Study Team
- Study Sponsored By
- Takeda
- Participants Required
- More Information
- Study ID:
NCT06108544